ScoreWhy is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with a 2.53% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.62 times
- The company has been able to generate a Return on Equity (avg) of 1.92% signifying low profitability per unit of shareholders funds
2
With a growth in Net Profit of 1225%, the company declared Very Positive results in Mar 26
- PBT LESS OI(Q) Highest at Rs 0.75 cr.
- PAT(Q) Highest at Rs 0.53 cr.
- NET SALES(Q) Highest at Rs 37.90 cr
3
Stock is technically in a Mildly Bullish range
- The stocks MACD and KST technical factors are also Bullish
4
With ROCE of 5.2, it has a Attractive valuation with a 1.9 Enterprise value to Capital Employed
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 150.23%, its profits have risen by 72% ; the PEG ratio of the company is 0.7
5
Majority shareholders : Promoters
6
Market Beating Performance
- The stock has generated a return of 150.23% in the last 1 year, much higher than market (BSE500) returns of 0.84%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Concord Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Concord Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Concord Drugs
150.23%
2.70
55.64%
Sensex
-4.95%
-0.37
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.78%
EBIT Growth (5y)
2.53%
EBIT to Interest (avg)
1.56
Debt to EBITDA (avg)
5.56
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.90
Tax Ratio
28.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.64%
ROE (avg)
1.92%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
95
Industry P/E
34
Price to Book Value
2.08
EV to EBIT
35.67
EV to EBITDA
24.96
EV to Capital Employed
1.85
EV to Sales
1.44
PEG Ratio
0.70
Dividend Yield
NA
ROCE (Latest)
5.20%
ROE (Latest)
2.18%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
PBT LESS OI(Q)
Highest at Rs 0.75 cr.
PAT(Q)
Highest at Rs 0.53 cr.
NET SALES(Q)
Highest at Rs 37.90 cr
PBDIT(Q)
Highest at Rs 1.49 cr.
EPS(Q)
Highest at Rs 0.40
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Net Sales - Quarterly
At Rs 37.90 cr has Grown at 264.77%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.75 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.53 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 37.90 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.49 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.40
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
